Podcast

Firsthand Experience With CAR T-Cell Therapy

Author(s):

In this episode, we spoke with a rare lymphoma survivor on how chimeric antigen receptor T-cell therapy saved her life.

With the approval of the first chimeric antigen receptor (CAR) T-cell therapy in 2017, the stars aligned just in time for one woman diagnosed with a rare lymphoma.

Following what was a stubborn cough and many misdiagnoses, Caitlin Buchanan was told she had primary mediastinal diffuse large B-cell lymphoma. After chemotherapy failed to work, she was given a second chance with CAR T-cell therapy — which is when immune cells are taken from a patient, re-engineered so that they seek out and destroy cancer, and are then re-introduced into the patient to treat their cancer.

In this week’s episode of “CURE® Talks Cancer,” Caitlin — who is now cancer-free – talked about her diagnosis, the shock of being told she had cancer and how CAR T-cell therapy changed her life.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Image of two doctors and text.
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Related Content